Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
Status:
Active, not recruiting
Trial end date:
2022-04-11
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well pazopanib hydrochloride works in
treating patients with von Hippel-Lindau syndrome. Pazopanib hydrochloride may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth.